603456 九洲药业
已收盘 07-17 15:00:00
资讯
新帖
简况
7月17日九洲药业跌9.79%，富国双债增强债券A基金重仓该股
证券之星 · 16:14
7月17日九洲药业跌9.79%，富国双债增强债券A基金重仓该股
九洲药业（603456）披露关于募集资金投资项目结项并将节余募集资金永久补充流动资金的议案，7月16日股价上涨0.88%
证券之星 · 07-16 22:18
九洲药业（603456）披露关于募集资金投资项目结项并将节余募集资金永久补充流动资金的议案，7月16日股价上涨0.88%
股市必读：九洲药业（603456）7月10日董秘有最新回复
证券之星 · 07-13
股市必读：九洲药业（603456）7月10日董秘有最新回复
九洲药业（603456）披露注销部分已回购股份公告，7月7日股价下跌4.31%
证券之星 · 07-07
九洲药业（603456）披露注销部分已回购股份公告，7月7日股价下跌4.31%
九洲药业：目前公司为艾力斯提供的服务主要集中于原料药CDMO
证券之星 · 07-06
九洲药业：目前公司为艾力斯提供的服务主要集中于原料药CDMO
每周股票复盘：九洲药业（603456）拟将节余募资903.28万补流
证券之星 · 07-05
每周股票复盘：九洲药业（603456）拟将节余募资903.28万补流
九洲药业：结合自建与产业链上下游并购等方式
证券之星 · 06-30
九洲药业：结合自建与产业链上下游并购等方式
九洲药业：2025年度回购股份注销尚处于通知债权人45天公示期内
证券之星 · 06-30
九洲药业：2025年度回购股份注销尚处于通知债权人45天公示期内
6月29日九洲药业涨5.76%，富国双债增强债券A基金重仓该股
证券之星 · 06-29
6月29日九洲药业涨5.76%，富国双债增强债券A基金重仓该股
九洲药业(603456.SH)子公司枸橼酸西地那非口崩片获药品注册证书
智通财经 · 06-26
九洲药业(603456.SH)子公司枸橼酸西地那非口崩片获药品注册证书
九洲药业（603456）披露全资子公司参与投资嘉兴隆峰创业投资合伙企业进展公告，6月25日股价下跌1.94%
证券之星 · 06-25
九洲药业（603456）披露全资子公司参与投资嘉兴隆峰创业投资合伙企业进展公告，6月25日股价下跌1.94%
九洲药业：稳步扩大小分子CDMO业务规模
证券之星 · 06-23
九洲药业：稳步扩大小分子CDMO业务规模
每周股票复盘：九洲药业（603456）子公司获两款药品注册证书
证券之星 · 06-20
每周股票复盘：九洲药业（603456）子公司获两款药品注册证书
股市必读：九洲药业（603456）6月17日董秘有最新回复
证券之星 · 06-18
股市必读：九洲药业（603456）6月17日董秘有最新回复
九洲药业(603456.SH)子公司获得药品注册证书
智通财经 · 06-16
九洲药业(603456.SH)子公司获得药品注册证书
九洲药业：公司投资者热线电话为0576-88706789
证券之星 · 06-12
九洲药业：公司投资者热线电话为0576-88706789
九洲药业：诺欣妥相关业务是重要组成部分
证券之星 · 06-08
九洲药业：诺欣妥相关业务是重要组成部分
九洲药业：公司积极推出2026年股份回购计划
证券之星 · 06-02
九洲药业：公司积极推出2026年股份回购计划
九洲药业：公司CDMO业务主要致力于向全球客户提供创新药临床前CMC，临床I、II、III期，NDA至全球上市全产业链的一站式优质服务
证券之星 · 06-02
九洲药业：公司CDMO业务主要致力于向全球客户提供创新药临床前CMC，临床I、II、III期，NDA至全球上市全产业链的一站式优质服务
九洲药业(603456.SH)：克立硼罗获批上市
智通财经 · 06-02
九洲药业(603456.SH)：克立硼罗获批上市
公司概况
公司名称：
浙江九洲药业股份有限公司
所属行业：
医药制造业
上市日期：
2014-10-10
主营业务：
浙江九洲药业股份有限公司的主营业务是提供一站式的医药定制研发和生产（CDMO）服务。公司的主要产品是合同定制类、抗感染类、中枢神经类药物、非甾体类药物、降血糖类药、贸易类及其他。公司荣获2025中国医药CDMO企业20强、国家知识产权示范企业、2024年度中国医药工业主营业务收入前100位企业、2025年EcoVadis企业社会责任评级“金牌”认证、全球优选合作伙伴奖、ESG责任企业奖等多项荣誉，同时公司已入选富时罗素社会责任指数系列。
发行价格：
15.43
{"stockData":{"symbol":"603456","market":"SH","secType":"STK","nameCN":"九洲药业","latestPrice":14.46,"timestamp":1784271600000,"preClose":16.03,"halted":0,"volume":38154825,"delay":0,"changeRate":-0.0979,"floatShares":882000000,"shares":882000000,"eps":0.7395,"marketStatus":"已收盘","change":-1.57,"latestTime":"07-17 15:00:00","open":15.56,"high":15.8,"low":14.45,"amount":573000000,"amplitude":0.0842,"askPrice":14.46,"askSize":823,"bidPrice":14.45,"bidSize":1013,"shortable":0,"etf":0,"ttmEps":0.7395,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784511000000},"marketStatusCode":5,"adr":0,"adjPreClose":16.03,"symbolType":"stock","openAndCloseTimeList":[[1784251800000,1784259000000],[1784264400000,1784271600000]],"highLimit":17.63,"lowLimit":14.43,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":881710028,"isCdr":false,"pbRate":1.43,"roa":"--","peRate":19.553753,"roe":"1.95%","epsLYR":0.82,"committee":0.300762,"marketValue":12750000000,"turnoverRate":0.0433,"status":1,"floatMarketCap":12750000000},"requestUrl":"/m/hq/s/603456/wiki","defaultTab":"wiki","newsList":[{"id":"2652405319","title":"7月17日九洲药业跌9.79%，富国双债增强债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652405319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652405319?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:14","pubTimestamp":1784276046,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日九洲药业跌9.79%，收盘报14.46元，换手率4.33%，成交量38.15万手，成交额5.73亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共17家，其中持有数量最多的公募基金为富国基金的富国双债增强债券A。富国双债增强债券A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700029534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651477440","title":"九洲药业（603456）披露关于募集资金投资项目结项并将节余募集资金永久补充流动资金的议案，7月16日股价上涨0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651477440","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651477440?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:18","pubTimestamp":1784211499,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，九洲药业报收于16.03元，较前一交易日上涨0.88%，最新总市值为141.34亿元。该股当日开盘15.6元，最高16.3元，最低15.35元，成交额达7.19亿元，换手率为5.11%。公告显示，公司于2026年7月16日在浙江省台州市椒江区外沙路99号召开2026年第二次临时股东会，会议审议通过了《关于募集资金投资项目结项并将节余募集资金永久补充流动资金的议案》，表决结果为同意99.83%，反对0.12%，弃权0.05%。其中持股5%以下股东对该议案的同意比例为97.50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600040150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603456","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651165467","title":"股市必读：九洲药业（603456）7月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651165467","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651165467?lang=zh_cn&edition=full","pubTime":"2026-07-13 01:23","pubTimestamp":1783876988,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，九洲药业报收于14.77元，上涨5.88%，换手率4.15%，成交量36.59万手，成交额5.31亿元。董秘最新回复投资者： 您好。请问截止到2026年7月8日，公司股东数是多少，谢谢。交易信息汇总资金流向7月10日主力资金净流入1110.9万元；游资资金净流入140.14万元；散户资金净流出1251.04万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300000720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649098514","title":"九洲药业（603456）披露注销部分已回购股份公告，7月7日股价下跌4.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649098514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649098514?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:25","pubTimestamp":1783416347,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，九洲药业报收于14.64元，较前一交易日下跌4.31%，最新总市值为129.08亿元。该股当日开盘15.0元，最高15.12元，最低14.6元，成交额达4.13亿元，换手率为3.16%。公告显示，公司于2026年7月7日注销已回购股份7,736,000股，占公司总股本的0.87%。回购股份已存放于回购专用证券账户，注销后公司总股本由889,446,028股减少至881,710,028股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700029444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603456","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649647913","title":"九洲药业：目前公司为艾力斯提供的服务主要集中于原料药CDMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2649647913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649647913?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:54","pubTimestamp":1783328066,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业(603456)07月06日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司与艾力斯在伏美替尼上的合作是只在原料药上还是拓展至制剂CDMO？九洲药业回复：您好，感谢您对公司的关注与支持，目前公司为艾力斯提供的服务主要集中于原料药CDMO，暂未涉及制剂CDMO，公司以高质量的产品交付能力获得客户的认可。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600022695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688578","BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649673694","title":"每周股票复盘：九洲药业（603456）拟将节余募资903.28万补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2649673694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649673694?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:15","pubTimestamp":1783188913,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，九洲药业报收于14.64元，较上周的12.84元上涨14.02%。本周关注点公司公告汇总：九洲药业拟将节余募集资金903.28万元永久补充流动资金。公司公告汇总浙江九洲药业股份有限公司拟将2020年非公开发行股票募投项目“收购中山制剂工厂100%股权并增资项目”结项，并将节余募集资金903.28万元（含利息）永久补充流动资金，实际金额以转出当日银行结息余额为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647536868","title":"九洲药业：结合自建与产业链上下游并购等方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2647536868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647536868?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:30","pubTimestamp":1782808259,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业(603456)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司是否有产业链相关的收购计划？如有，请及时告知。九洲药业回复：您好，感谢您对公司的关注与支持，公司将结合自建与产业链上下游并购等方式，推动业务实现快速增长，后续具体进展详见公司在上海证券交易所披露的相关公告，谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000029509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647350465","title":"九洲药业：2025年度回购股份注销尚处于通知债权人45天公示期内","url":"https://stock-news.laohu8.com/highlight/detail?id=2647350465","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647350465?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:30","pubTimestamp":1782808232,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业06月30日在投资者关系平台上答复投资者关心的问题。九洲药业回复：您好，感谢您对公司的关注与支持，股价波动受多重非可控因素影响；2025年度回购股份注销尚处于通知债权人45天公示期内，到期后我们将及时办理注销手续；公司正在持续推进2026年回购股份计划，请您关注公司在上海证券交易所网站披露的回购进展公告，谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000029478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647241203","title":"6月29日九洲药业涨5.76%，富国双债增强债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647241203","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647241203?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:33","pubTimestamp":1782721980,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日九洲药业涨5.76%，收盘报13.58元，换手率3.65%，成交量32.47万手，成交额4.33亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共17家，其中持有数量最多的公募基金为富国基金的富国双债增强债券A。富国双债增强债券A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646333255","title":"九洲药业(603456.SH)子公司枸橼酸西地那非口崩片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646333255","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646333255?lang=zh_cn&edition=full","pubTime":"2026-06-26 15:35","pubTimestamp":1782459309,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业 发布公告，近日，公司控股子公司南京康川济医药科技有限公司收到国家药品监督管理局核准签发的枸橼酸西地那非口崩片的《药品注册证书》。枸橼酸西地那非口崩片为辉瑞基于以患者为中心开发的西地那非迭代剂型，2019年在中国批准进口。目前国内获得该药品注册证书的厂家主要为四川科伦药业股份有限公司、广东泰恩康医药股份有限公司等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九洲药业(603456.SH)子公司枸橼酸西地那非口崩片获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646809679","title":"九洲药业（603456）披露全资子公司参与投资嘉兴隆峰创业投资合伙企业进展公告，6月25日股价下跌1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646809679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646809679?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:24","pubTimestamp":1782397460,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，九洲药业报收于13.14元，较前一交易日下跌1.94%，最新总市值为116.87亿元。该股当日开盘13.2元，最高13.33元，最低12.76元，成交额达2.95亿元，换手率为2.55%。近日，浙江九洲药业股份有限公司发布《关于全资子公司参与投资嘉兴隆峰创业投资合伙企业的进展公告》。本次合伙人变更后，普通合伙人1名，有限合伙人6名。本次新增合伙人对公司财务状况和经营成果无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645154884","title":"九洲药业：稳步扩大小分子CDMO业务规模","url":"https://stock-news.laohu8.com/highlight/detail?id=2645154884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645154884?lang=zh_cn&edition=full","pubTime":"2026-06-23 17:03","pubTimestamp":1782205408,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业06月23日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603456","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644063760","title":"每周股票复盘：九洲药业（603456）子公司获两款药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063760","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644063760?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:30","pubTimestamp":1781893834,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，九洲药业报收于13.12元，较上周的12.78元上涨2.66%。本周，九洲药业6月18日盘中最高价报13.24元。本周关注点公司公告汇总：子公司获富马酸伏诺拉生片和西格列汀二甲双胍缓释片药品注册证书公司公告汇总浙江九洲药业股份有限公司子公司九洲生物医药（台州）有限公司、浙江九洲生物医药有限公司近日收到国家药品监督管理局核准签发的富马酸伏诺拉生片、西格列汀二甲双胍缓释片《药品注册证书》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603456","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644172381","title":"股市必读：九洲药业（603456）6月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644172381","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644172381?lang=zh_cn&edition=full","pubTime":"2026-06-18 01:32","pubTimestamp":1781717532,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，九洲药业报收于12.97元，上涨2.85%，换手率2.11%，成交量18.74万手，成交额2.42亿元。富马酸伏诺拉生片用于反流性食管炎及幽门螺杆菌根除，注册分类为化学药品4类，上市许可持有人为九洲生物医药（台州）有限公司。西格列汀二甲双胍缓释片适用于成人2型糖尿病患者，注册分类为化学药品3类，上市许可持有人为浙江九洲生物医药有限公司，生产单位为广州玻思韬控释药业有限公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800001383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603456","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643734765","title":"九洲药业(603456.SH)子公司获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2643734765","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643734765?lang=zh_cn&edition=full","pubTime":"2026-06-16 15:42","pubTimestamp":1781595772,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)发布公告，近日，公司子公司九洲生物医药(台州)有限公司、浙江九洲生物医药有限公司收到国家药品监督管理局核准签发的富马酸伏诺拉生片、西格列汀二甲双胍缓释片的《药品注册证书》。富马酸伏诺拉生片适用于反流性食管炎，与适当的抗生素联用以根除幽门螺杆菌。西格列汀二甲双胍缓释片适用于正在接受西格列汀和二甲双胍缓释片联合治疗的成人2型糖尿病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642265517","title":"九洲药业：公司投资者热线电话为0576-88706789","url":"https://stock-news.laohu8.com/highlight/detail?id=2642265517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642265517?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:27","pubTimestamp":1781252868,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业(603456)06月12日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问可否告知董秘办电话多少，谢谢！九洲药业回复：您好，感谢您对公司的关注与支持，公司投资者热线电话为：0576-88706789。谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200025345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641104082","title":"九洲药业：诺欣妥相关业务是重要组成部分","url":"https://stock-news.laohu8.com/highlight/detail?id=2641104082","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641104082?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:54","pubTimestamp":1780905248,"startTime":"0","endTime":"0","summary":"诺欣妥相关专利延期对公司未来业绩的影响存在不确定性，公司业绩受到宏观经济环境、行业发展趋势、市场竞争、客户需求以及公司经营管理等多重因素影响，具体经营情况详见公司于上海证券交易所网站披露的定期报告及相关公告，敬请广大投资者理性投资，注意投资风险，谢谢！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800017674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","603456","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640978919","title":"九洲药业：公司积极推出2026年股份回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2640978919","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640978919?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:19","pubTimestamp":1780391947,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业(603456)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是觉得当前股价不够低吗，要把回购审议会议定到6月10日召开？中兴通讯发布回购方案，股价能涨停。公司发布回购方案股价一再新低，公司到底差在哪了？九洲药业回复：您好，感谢您对公司的关注与支持，股价波动受多重非可控因素影响，公司为进一步稳定股价，增强投资者信心，公司积极推出2026年股份回购计划，具体内容请持续关注公司于上海证券交易所网站披露的相关公告，谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640919994","title":"九洲药业：公司CDMO业务主要致力于向全球客户提供创新药临床前CMC，临床I、II、III期，NDA至全球上市全产业链的一站式优质服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2640919994","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640919994?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:19","pubTimestamp":1780391947,"startTime":"0","endTime":"0","summary":"证券之星消息，九洲药业(603456)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问贵司是否属于能承接后端订单、复杂新分子和全球临床需求的公司呢？九洲药业回复：您好，感谢您对公司的关注与支持，公司CDMO业务主要致力于向全球客户提供创新药临床前CMC，临床I、II、III期，NDA至全球上市全产业链的一站式优质服务，谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200032885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0070","159992","06978","BK0239","BK1161","603456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640677916","title":"九洲药业(603456.SH)：克立硼罗获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2640677916","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640677916?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:49","pubTimestamp":1780390154,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九洲药业(603456.SH)发布公告，近日，公司收到国家药品监督管理局颁发的关于克立硼罗的《化学原料药上市申请批准通知书》。该药品是一种磷酸二酯酶4(PDE-4)抑制剂，其制剂克立硼罗软膏适用于3月龄及以上轻度至中度特应性皮炎患者的局部外用治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603456","IPOS","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784282789326,"stockEarnings":[{"period":"1week","weight":0.1491},{"period":"1month","weight":0.2712},{"period":"3month","weight":-0.0506},{"period":"6month","weight":-0.1773},{"period":"1year","weight":0.0005},{"period":"ytd","weight":-0.0973}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0512},{"period":"3month","weight":-0.0417},{"period":"6month","weight":-0.0535},{"period":"1year","weight":0.1081},{"period":"ytd","weight":-0.0218}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江九洲药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"59705人(较上一季度增加4.62%)","perCapita":"14767股","listingDate":"2014-10-10","address":"浙江省台州市椒江区外沙工业区","registeredCapital":"88171万元","survey":" 浙江九洲药业股份有限公司的主营业务是提供一站式的医药定制研发和生产（CDMO）服务。公司的主要产品是合同定制类、抗感染类、中枢神经类药物、非甾体类药物、降血糖类药、贸易类及其他。公司荣获2025中国医药CDMO企业20强、国家知识产权示范企业、2024年度中国医药工业主营业务收入前100位企业、2025年EcoVadis企业社会责任评级“金牌”认证、全球优选合作伙伴奖、ESG责任企业奖等多项荣誉，同时公司已入选富时罗素社会责任指数系列。","listedPrice":15.43},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九洲药业(603456)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九洲药业(603456)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九洲药业,603456,九洲药业股票,九洲药业股票老虎,九洲药业股票老虎国际,九洲药业行情,九洲药业股票行情,九洲药业股价,九洲药业股市,九洲药业股票价格,九洲药业股票交易,九洲药业股票购买,九洲药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九洲药业(603456)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九洲药业(603456)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}